GlassScriptPhysician profile
Khaled M Abdalla
NPI 1750811428
$10,379.69
in general payments reported to CMS, 2019-2025
44 companies · $6,424 in 2025
The $6,424 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.50 · 2023: $991 · 2024: $2,937 · 2025: $6,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,737 · Consulting Fee: $3,401 · Travel and Lodging: $844 · Education: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.27 |
| Consulting Fee | $3,400.50 |
| Travel and Lodging | $844.11 |
| Education | $371.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,995.59 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Biogen, INC. | $1,908.32 | 2023-2025 | Tysabri, Vumerity, Tecfidera |
| Alexion Pharmaceuticals, INC. | $594.13 | 2023-2025 | Ultomiris, Soliris |
| Ucb, INC. | $481.39 | 2023-2025 | Rystiggo, Fintepla, Briviact |
| Emd Serono, INC. | $370.65 | 2023-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $363.63 | 2023-2025 | Botox, Qulipta, Ubrelvy |
| Celgene Corporation | $327.14 | 2024-2025 | Zeposia |
| Lundbeck LLC | $280.45 | 2023-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $255.75 | 2024-2025 | |
| Lilly USA, LLC | $238.56 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Amgen INC. | $230.54 | 2024-2025 | Uplizna |
| Sk Life Science, INC. | $194.66 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $174.96 | 2023-2025 | |
| Inspire Medical Systems, INC. | $173.82 | 2023-2025 | Inspire |
| Tg Therapeutics, INC. | $171.14 | 2023-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $153.81 | 2024-2025 | Ponvory |
| Argenx US, INC. | $136.03 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech, INC. | $125.56 | 2024 | Ocrevus |
| Astrazeneca Pharmaceuticals LP | $88.53 | 2024-2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $78.95 | 2023-2024 | Austedo Xr |
| Ani Pharmaceuticals, INC. | $78.15 | 2023-2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $77.07 | 2024-2025 | Acthar |
| Catalyst Pharmaceuticals, INC. | $76.92 | 2024-2025 | |
| Axsome Therapeutics, INC. | $74.76 | 2023-2025 | Sunosi, Symbravo |
| Eisai INC. | $73.51 | 2024-2025 | |
| Neurelis, INC. | $73.29 | 2023-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $68.30 | 2023-2024 | Rytary, Ongentys 50mg Capsules 30 |
| Tanabe Pharma America, INC. | $65.44 | 2024-2025 | Radicava |
| Harmony Biosciences LLC | $53.67 | 2025 | |
| Merz Pharmaceuticals, LLC | $46.53 | 2023-2024 | Xeomin |
| Ge Healthcare | $39.65 | 2025 | |
| Pfizer INC. | $36.15 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.00 | 2025 | Zeposia |
| Microtransponder, INC. | $27.47 | 2024 | |
| Aquestive Therapeutics, INC. | $26.91 | 2025 | |
| Masimo Corporation | $26.50 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.67 | 2024 | Onpattro |
| Abbott Laboratories | $21.47 | 2025 | Infinity |
| Cycle Pharmaceuticals INC | $20.76 | 2025 | Bafiertam, Tascenso Odt |
| Biocodex, INC. | $20.28 | 2025 | |
| Acadia Pharmaceuticals INC | $19.63 | 2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $18.99 | 2024 | Rexulti |
| Corium, LLC | $18.09 | 2023 | Adlarity |
| Csl Behring | $15.87 | 2023 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Abdalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.